ZFIN ID: ZDB-FISH-151105-26
Fish name: gz15Tg; gz32Tg
Genotype: gz15Tg; gz32Tg
Targeting Reagent: none
HUMAN DISEASE MODELED by gz15Tg; gz32Tg
Human Disease Conditions Citations
hepatocellular carcinoma chemical treatment by environment: doxycycline HCl Li et al., 2019
GENE EXPRESSION
Gene expression in gz15Tg; gz32Tg
RNA expression No data available
PHENOTYPE
Phenotype in gz15Tg; gz32Tg
Phenotype Conditions Figures
hepatocyte apoptotic process increased process quality, abnormal chemical treatment: doxycycline monohydrate Fig. 5 with image from Yan et al., 2015
hepatocyte apoptotic process increased process quality, abnormal chemical treatment: doxycycline monohydrate, chemical treatment: NF-kappaB inhibitor Fig. 5 with image from Yan et al., 2015
hepatocyte cell population proliferation increased process quality, abnormal chemical treatment: FPR A14, chemical treatment: doxycycline monohydrate Fig. 5 with image from Yan et al., 2015
hepatocyte cell population proliferation increased process quality, abnormal chemical treatment: doxycycline monohydrate Fig. 5 with image from Yan et al., 2015
liver DsRed expression amount, ameliorated chemical treatment by environment: nanoparticle, chemical treatment by environment: doxorubicin, chemical treatment by environment: doxycycline HCl Fig. 6 from Li et al., 2019
liver DsRed expression amount, ameliorated chemical treatment by environment: doxorubicin, chemical treatment by environment: doxycycline HCl Fig. 6 from Li et al., 2019
liver hyperplastic, abnormal chemical treatment: doxycycline monohydrate, chemical treatment: NF-kappaB inhibitor Fig. 6 with image from Yan et al., 2015
liver DsRed expression increased amount, abnormal chemical treatment by environment: doxycycline HCl Fig. 6 from Li et al., 2019
liver increased volume, abnormal chemical treatment: doxycycline monohydrate Fig. 2 from Chew et al., 2014
liver neoplastic, abnormal chemical treatment by environment: doxycycline HCl Fig. 6 from Li et al., 2019
liver neoplastic, ameliorated chemical treatment by environment: doxorubicin, chemical treatment by environment: doxycycline HCl Fig. 6 from Li et al., 2019
liver neoplastic, ameliorated chemical treatment by environment: nanoparticle, chemical treatment by environment: doxorubicin, chemical treatment by environment: doxycycline HCl Fig. 6 from Li et al., 2019
liver hepatocellular carcinoma increased occurrence, abnormal chemical treatment: FPR A14, chemical treatment: doxycycline monohydrate Fig. 6 with image from Yan et al., 2015
liver hepatocellular carcinoma increased occurrence, abnormal chemical treatment: doxycycline monohydrate Fig. 6 with image from Yan et al., 2015

CITATIONS  (3)